Prostate CancerNCT01314456
3D Recording of a Trans-rectal Prostate Biopsy
A study testing NaviGo in people with Prostate Cancer and Benign Prostatic Hyperplasia, run by HaEmek Medical Center, Israel at 1 site in Israel.
Trial summary
Prostate biopsy is performed by multiple consecutive biopsy needle insertion into the prostate gland under a trans-rectal ultrasound probe guidance. Today, the performing physician navigates the needle using a momentary 2D ultrasound image (longitudinal and transverse B mode) without any record of the full prostate… Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostate Cancer, Benign Prostatic Hyperplasia
- What is being tested?
- NaviGo
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 50 participants
- Where
- 1 siteIsrael
- Study dates
- Mar 2011to Dec 2011
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age 18 years or older
- Planned for trans-rectal prostate biopsy
- Signed informed consent
Who cannot join
- Patient's unwilling to participate
- Patients with metal prosthetics
Trial locations and contacts
1 site in 1 country.
About this study
Prostate biopsy is performed by multiple consecutive biopsy needle insertion into the prostate gland under a trans-rectal ultrasound probe guidance.
Today, the performing physician navigates the needle using a momentary 2D ultrasound image (longitudinal and transverse B mode) without any record of the full prostate boundaries or previous biopsies' location.
This study's Objectives are to record the trans-rectal biopsy procedure including the initial scan and the needle biopsy location and to modulate a 3D model of the prostate with accurate display the locations of the various biopsies taken during the procedure.
Read the detailed description
3D record of a trans-rectal prostate biopsy
Clinical Study Protocol Study no: NaviGo -01
Sponsor: UC-CARE. Apollo Bld. 3rd fl. Hi-Tech Park P.O.Box 67 Yokneam 20692 Israel Tel: 972-4-9097427 Fax:972-4-9937323
Feb. 2011 Version: 02
ABBREVIATIONS:
3D: 3 Dimensional 2D: 2 Dimensional TR: Trans-Rectal
- PROTOCOL SUMMARY Title: 3D recording of a trans-rectal prostate biopsy Device: Navigo™ Study Objectives: 1) To record the trans-rectal biopsy procedure including the initial scan and the needle biopsy location 2) To modulate a 3D model of the prostate and accurately display the locations of the various biopsies taken during the procedure Study Design: Open prospective study. Recruitment target: 50 patients Study Population: Patients undergoing trans-rectal prostate biopsy Study endpoint: Accurate 3D modelling of the prostate and the biopsy procedure Principal Investigator Co-operating Company and Sponsor: Dr. Michael Cohen UC-CARE. Yokneam, Israel
- INTRODUCTION Prostate biopsy is performed by multiple consecutive biopsy needle insertion into the prostate gland under the trans-rectal ultrasound probe guidance. The needle is inserted through a designated needle guide on the ultrasound probe, through the rectum wall and into the prostate gland.
Today, the performing physician navigates the needle using a momentary 2D ultrasound image (longitudinal and transverse B mode) without any record of the full prostate boundaries or previous biopsies' location. By recording the procedure the Navigo™ system will generate and display in off-line an accurate 3D model of the prostate and position the biopsies taken in the prostatic volume.
- OBJECTIVES AND RATIONALE 3.1 Study objectives
- To record the trans-rectal biopsy procedure including the initial scan and the needle biopsy location 2) To modulate a 3D model of the prostate and accurately display the locations of the various biopsies taken during the procedure
3.2 Rationale
The Navigo™ system is a noninvasive system that allows the physician to accurately record the biopsy procedure without changing the imaging system, the biopsy routine or the techniques used today to scan and guide the biopsy needle insertion. The ability to create an accurate 3D model of the prostate and accurately position the biopsy needle location will allow the performing physician a more precise navigation and easier and more accurate biopsy within the prostate volume and enable a better analysis of the procedure and the pathological results, hence improved clinical outcomes with intended therapy or surveillance ( i.e.- prepare for follow-up biopsy procedure if needed).
- DEVICE DESCRIPTION AND INTENDED USE The Navigo™ system is comprised of two main elements: a standard laptop computer with a digitizer input to record incoming video input (from the ultrasound system), and an electro-magnetic 3D tracking system. The 3D tracking system is connected via USB to the laptop computer, the transmitter is placed beneath the patient's mattress and two sensors are attached,- one to the ultrasound probe (at the base/ non invasive part of the probe) and the other to the patient's back.
The Navigo™ system tracks and records the location of the ultrasound probe and the incoming video from the ultrasound system. The patient's movement is recorded and compensated when the ultrasound images are placed with reference to each other. In post procedure, the physician defines the boundaries of the prostate on selected ultrasound images and a 3D model of the prostate is displayed with all recorded biopsy specimens' locations displayed in the prostatic volume. The physician will be able to examine in post analysis the scattering quality of the biopsy specimens in the prostatic volume and update the pathology results. The 3D model can be rotated, manipulated and displayed in the physician's preferable choice.
The Navigo™ system is intended to record and display in 3D the biopsy procedure of any patient undergoing a prostate trans-rectal biopsy. The Navigo™ system is intended to record all the data from the initial scan, the volume measurements, and the biopsy needle insertion. All the images are saved and can be reviewed in post analysis, the needle location can be updated according to the physician's marking on the recorded ultrasound image and the pathology results will be displayed in color on the 3D model.
- METHODS AND PROCEDURES 5.1 Study Design
The study is an open prospective study
- Examination procedure:
- The trans-rectal ultrasound guided prostate biopsy procedure will be conducted with no change what so ever from the currently conducted procedure.
- The exceptions to the normal procedure is the addition of the flat transmitter under the patients mattress, the 2 external attached sensors and the recording of the procedure via the video-out put of the ultrasound using the Navigo™ system.
- The 3D model will be compared with the recorded ultrasound images by the physician
- The recorded data will be processed off-line (post biopsy /off-line analysis).
- The analysis of the results will be completed in post procedure by the physician.
5.2 Trial Procedure
- A short one-time calibration of the Navigo™ system with the ultrasound system will be completed by a trained technician (UC-CARE's technician)
- The transmitter will be placed beneath the patient's mattress and the body sensor will be attached to the patients' back using a regular disposable medical sticker.
- The trans-rectal ultrasound probe will be held by the physician and controlled throughout the procedure according to the existing current biopsy protocol, without any alterations.
- The common ultrasound video output will be connected to the video input of the Navigo™ system
- Patient's identifications will be filled to allow proper post examination analysis
- Following the initial scan of the prostate and the volume measurements the Navigo™ system will record the data and store it for post analysis
- In the 3D biopsy screen a 3D model of the prostate will be displayed with record of all needle biopsy locations as recorded during the procedure.
- The pathology results can be loaded to the Navigo™ system and displayed on the 3D model
- SUBJECT POPULATION SELECTION 6.1 Inclusion Criteria
- Eligibility -
- Age 18 years or older
- Planned for trans-rectal prostate biopsy
- Signed informed consent
6.2 Exclusion criteria
- Patient's unwilling to participate
- Patients with metal prosthetics
- POTENTIAL BENEFITS TO SUBJECTS No immediate benefits are expected to be gained by the subjects participating in the study as the 3D modeling and the display is completed post procedure. The procedure will be carried out exactly as it would have been without the Navigo™ system participating in the biopsy procedure. The post procedure 3D model display with the biopsy specimen's location may enable better data analysis.
- POTENTIAL RISKS TO SUBJECTS The Navigo™ system is a passive system that does not require any change in the procedure performed today. The various components do not come in direct contact with the patient or the physician and the computer and 3D tracking system are well within the required safety protocols.
The Navigo system has been approved by the CE. The 3D tracking system is approved by the FDA for medical use and is classified as Type CF which is the most stringent classification, being required for those applications where the applied part is in direct conductive contact with the heart or other applications as considered necessary. The 3D tracking system is also part of an approved Helsinki trial in Bnei-zion hospital (monitoring of the birth progress, trial initiated by Dr. Yoav Paltieli) Adverse effects are not expected according to the accumulated experience with the 3D tracking system. Similarly, the Navigo™ system is not expected to add to the procedure any pain or discomfort to the patients.
- SUBJECT RECUITMENT Study population will be recruited from the pool of patients who are scheduled for trans-rectal biopsy procedure
- DATA ANALYSIS
The data analysis will include the following steps:
- Post procedure display of the prostate's 3D model and the location of the various biopsy specimens taken during the procedure in the prostatic volume
- Comparison of the results with the physician analysis of the specimens location as derived from the images themselves
- REFERENCE
- Ultrasonography and biopsy of the prostate. Ramey et al., Chapter 92. Campbell-Walsh Urology. Elsevier 2007.
- Prostate biopsies guided by three-dimensional real-time (4-D) transrectal ultrasonography on a phantom: comparative study versus two-dimensional transrectal ultrasound-guided biopsies. Long, Eur.Urol, 2007 Oct;52(4):1097-104.
- Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Scattoni , Eur Urol. 2007 Nov;52(5):1309-22 .
- Appropriate Patient Selection in the Focal Treatment of Prostate Cancer: The Role of Transperineal 3-Dimensional Pathologic Mapping of the Prostate-A 4-Year Experience. Barzell. Urology 70 ( suppl. 6a) dec. 2007
- The lottery of conventional prostate biopsy. Andriole. Nat. Rev. urol. P-189 , V-6, Apr. 2009
- Will focal therapy become a standard of care for men with localized prostate cacner? Ahmed. Nat. Clin.Pract. Oncol. 4(11)
- Conditions
- Prostate Cancer, Benign Prostatic Hyperplasia
- Being tested
- NaviGo
- Keywords
- Prostate biopsy, Trans-rectal ultrasound, Prostate cancer
- Medical subject headings
- Prostatic Neoplasms, Prostatic Hyperplasia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NaviGoDevice
Also called 3D recording of a trans-rectal prostate biopsy
Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
| Study group | Role | What they receive |
|---|---|---|
| NaviGo | Experimental | Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate. Receives: Device: NaviGo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Create 3D model of the prostate and accurately display the locations of the various biopsies taken during the procedure
Measured: Post procedure ( off-line ) within a 3-5 working days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Mar 2011 (estimated)
- Study startMar 2011
- Primary completionDec 2011 (estimated)
- Study completionDec 2011 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- HaEmek Medical Center, Israel
- Sponsor type
- University, hospital or other
- Collaborators
- Bnai Zion Medical Center, Barzilai Medical Center, Meir Medical Center
- Investigators
- Boris Yudkevich, MD, Study director, HaEmek Medical Center, IsraelGenady Zelichenko, MD, Study director, HaEmek Medical Center, IsraelIlan Leibovich, MD, Principal investigator, Meir Medical center, IsraelGiora Tikotchinsky, MD, Study director, Meir medical center, IsraelMoshe Shalev, MD, Study director, Meir medical center, IsraelOfer Nativ, Prof., MD, Principal investigator, Bnei-Zion medical center, IsraelShmuel Cytron, MD, Principal investigator, Barzilai medical center, IsraelMichael Cohen, MD, Principal investigator, HaEmek Medical Center, Israel
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT01314456
- Sponsor's protocol ID
- NaviGo- 01
- Other IDs
- 3D TRUS Bx recording
- Status last verified
- Mar 2011
- First submitted
- 11 Mar 2011
- Last updated
- 16 Mar 2011
- Results posted
- No
- Data monitoring committee
- No
Study at a glance
From the registry record, last updated by the sponsor on 16 Mar 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- 3D Recording of a Trans-rectal Prostate Biopsy
- ClinicalTrials.gov ID
- NCT01314456
- Acronym / sponsor ID
- NaviGo- 01
- Conditions
- Prostate Cancer, Benign Prostatic Hyperplasia
- Keywords
- Prostate biopsy, Trans-rectal ultrasound, Prostate cancer
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- HaEmek Medical Center, IsraelUniversity, hospital or other
- Collaborators
- Bnai Zion Medical Center, Barzilai Medical Center, Meir Medical Center
- Study start
- Mar 2011
- Primary completion
- Dec 2011 (estimated)
- Study completion
- Dec 2011 (estimated)
- First posted
- 14 Mar 2011 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Prostate biopsy is performed by multiple consecutive biopsy needle insertion into the prostate gland under a trans-rectal ultrasound probe guidance.
Today, the performing physician navigates the needle using a momentary 2D ultrasound image (longitudinal and transverse B mode) without any record of the full prostate boundaries or previous biopsies' location.
This study's Objectives are to record the trans-rectal biopsy procedure including the initial scan and the needle biopsy location and to modulate a 3D model of the prostate with accurate display the locations of the various biopsies taken during the procedure.
Detailed description
3D record of a trans-rectal prostate biopsy
Clinical Study Protocol Study no: NaviGo -01
Sponsor: UC-CARE. Apollo Bld. 3rd fl. Hi-Tech Park P.O.Box 67 Yokneam 20692 Israel Tel: 972-4-9097427 Fax:972-4-9937323
Feb. 2011 Version: 02
ABBREVIATIONS:
3D: 3 Dimensional 2D: 2 Dimensional TR: Trans-Rectal
- PROTOCOL SUMMARY Title: 3D recording of a trans-rectal prostate biopsy Device: Navigo™ Study Objectives: 1) To record the trans-rectal biopsy procedure including the initial scan and the needle biopsy location 2) To modulate a 3D model of the prostate and accurately display the locations of the various biopsies taken during the procedure Study Design: Open prospective study. Recruitment target: 50 patients Study Population: Patients undergoing trans-rectal prostate biopsy Study endpoint: Accurate 3D modelling of the prostate and the biopsy procedure Principal Investigator Co-operating Company and Sponsor: Dr. Michael Cohen UC-CARE. Yokneam, Israel
- INTRODUCTION Prostate biopsy is performed by multiple consecutive biopsy needle insertion into the prostate gland under the trans-rectal ultrasound probe guidance. The needle is inserted through a designated needle guide on the ultrasound probe, through the rectum wall and into the prostate gland.
Today, the performing physician navigates the needle using a momentary 2D ultrasound image (longitudinal and transverse B mode) without any record of the full prostate boundaries or previous biopsies' location. By recording the procedure the Navigo™ system will generate and display in off-line an accurate 3D model of the prostate and position the biopsies taken in the prostatic volume.
- OBJECTIVES AND RATIONALE 3.1 Study objectives
- To record the trans-rectal biopsy procedure including the initial scan and the needle biopsy location 2) To modulate a 3D model of the prostate and accurately display the locations of the various biopsies taken during the procedure
3.2 Rationale
The Navigo™ system is a noninvasive system that allows the physician to accurately record the biopsy procedure without changing the imaging system, the biopsy routine or the techniques used today to scan and guide the biopsy needle insertion. The ability to create an accurate 3D model of the prostate and accurately position the biopsy needle location will allow the performing physician a more precise navigation and easier and more accurate biopsy within the prostate volume and enable a better analysis of the procedure and the pathological results, hence improved clinical outcomes with intended therapy or surveillance ( i.e.- prepare for follow-up biopsy procedure if needed).
- DEVICE DESCRIPTION AND INTENDED USE The Navigo™ system is comprised of two main elements: a standard laptop computer with a digitizer input to record incoming video input (from the ultrasound system), and an electro-magnetic 3D tracking system. The 3D tracking system is connected via USB to the laptop computer, the transmitter is placed beneath the patient's mattress and two sensors are attached,- one to the ultrasound probe (at the base/ non invasive part of the probe) and the other to the patient's back.
The Navigo™ system tracks and records the location of the ultrasound probe and the incoming video from the ultrasound system. The patient's movement is recorded and compensated when the ultrasound images are placed with reference to each other. In post procedure, the physician defines the boundaries of the prostate on selected ultrasound images and a 3D model of the prostate is displayed with all recorded biopsy specimens' locations displayed in the prostatic volume. The physician will be able to examine in post analysis the scattering quality of the biopsy specimens in the prostatic volume and update the pathology results. The 3D model can be rotated, manipulated and displayed in the physician's preferable choice.
The Navigo™ system is intended to record and display in 3D the biopsy procedure of any patient undergoing a prostate trans-rectal biopsy. The Navigo™ system is intended to record all the data from the initial scan, the volume measurements, and the biopsy needle insertion. All the images are saved and can be reviewed in post analysis, the needle location can be updated according to the physician's marking on the recorded ultrasound image and the pathology results will be displayed in color on the 3D model.
- METHODS AND PROCEDURES 5.1 Study Design
The study is an open prospective study
- Examination procedure:
- The trans-rectal ultrasound guided prostate biopsy procedure will be conducted with no change what so ever from the currently conducted procedure.
- The exceptions to the normal procedure is the addition of the flat transmitter under the patients mattress, the 2 external attached sensors and the recording of the procedure via the video-out put of the ultrasound using the Navigo™ system.
- The 3D model will be compared with the recorded ultrasound images by the physician
- The recorded data will be processed off-line (post biopsy /off-line analysis).
- The analysis of the results will be completed in post procedure by the physician.
5.2 Trial Procedure
- A short one-time calibration of the Navigo™ system with the ultrasound system will be completed by a trained technician (UC-CARE's technician)
- The transmitter will be placed beneath the patient's mattress and the body sensor will be attached to the patients' back using a regular disposable medical sticker.
- The trans-rectal ultrasound probe will be held by the physician and controlled throughout the procedure according to the existing current biopsy protocol, without any alterations.
- The common ultrasound video output will be connected to the video input of the Navigo™ system
- Patient's identifications will be filled to allow proper post examination analysis
- Following the initial scan of the prostate and the volume measurements the Navigo™ system will record the data and store it for post analysis
- In the 3D biopsy screen a 3D model of the prostate will be displayed with record of all needle biopsy locations as recorded during the procedure.
- The pathology results can be loaded to the Navigo™ system and displayed on the 3D model
- SUBJECT POPULATION SELECTION 6.1 Inclusion Criteria
- Eligibility -
- Age 18 years or older
- Planned for trans-rectal prostate biopsy
- Signed informed consent
6.2 Exclusion criteria
- Patient's unwilling to participate
- Patients with metal prosthetics
- POTENTIAL BENEFITS TO SUBJECTS No immediate benefits are expected to be gained by the subjects participating in the study as the 3D modeling and the display is completed post procedure. The procedure will be carried out exactly as it would have been without the Navigo™ system participating in the biopsy procedure. The post procedure 3D model display with the biopsy specimen's location may enable better data analysis.
- POTENTIAL RISKS TO SUBJECTS The Navigo™ system is a passive system that does not require any change in the procedure performed today. The various components do not come in direct contact with the patient or the physician and the computer and 3D tracking system are well within the required safety protocols.
The Navigo system has been approved by the CE. The 3D tracking system is approved by the FDA for medical use and is classified as Type CF which is the most stringent classification, being required for those applications where the applied part is in direct conductive contact with the heart or other applications as considered necessary. The 3D tracking system is also part of an approved Helsinki trial in Bnei-zion hospital (monitoring of the birth progress, trial initiated by Dr. Yoav Paltieli) Adverse effects are not expected according to the accumulated experience with the 3D tracking system. Similarly, the Navigo™ system is not expected to add to the procedure any pain or discomfort to the patients.
- SUBJECT RECUITMENT Study population will be recruited from the pool of patients who are scheduled for trans-rectal biopsy procedure
- DATA ANALYSIS
The data analysis will include the following steps:
- Post procedure display of the prostate's 3D model and the location of the various biopsy specimens taken during the procedure in the prostatic volume
- Comparison of the results with the physician analysis of the specimens location as derived from the images themselves
- REFERENCE
- Ultrasonography and biopsy of the prostate. Ramey et al., Chapter 92. Campbell-Walsh Urology. Elsevier 2007.
- Prostate biopsies guided by three-dimensional real-time (4-D) transrectal ultrasonography on a phantom: comparative study versus two-dimensional transrectal ultrasound-guided biopsies. Long, Eur.Urol, 2007 Oct;52(4):1097-104.
- Extended and saturation prostatic biopsy in the diagnosis and characterisation of prostate cancer: a critical analysis of the literature. Scattoni , Eur Urol. 2007 Nov;52(5):1309-22 .
- Appropriate Patient Selection in the Focal Treatment of Prostate Cancer: The Role of Transperineal 3-Dimensional Pathologic Mapping of the Prostate-A 4-Year Experience. Barzell. Urology 70 ( suppl. 6a) dec. 2007
- The lottery of conventional prostate biopsy. Andriole. Nat. Rev. urol. P-189 , V-6, Apr. 2009
- Will focal therapy become a standard of care for men with localized prostate cacner? Ahmed. Nat. Clin.Pract. Oncol. 4(11)
Study design
- Primary purpose
- Diagnosis
- Allocation
- Non-randomised
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| NaviGo | Experimental | Device: NaviGoVideo recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate. |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (3 listed)
- Age 18 years or older
- Planned for trans-rectal prostate biopsy
- Signed informed consent
Key exclusion criteria (2 listed)
- Patient's unwilling to participate
- Patients with metal prosthetics
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NaviGoAlso: 3D recording of a trans-rectal prostate biopsyVideo recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate. | Device | NaviGo |
Primary outcome
Create 3D model of the prostate and accurately display the locations of the various biopsies taken during the procedure
Time frame: Post procedure ( off-line ) within a 3-5 working days
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 16 Mar 2011.
Related trials for Prostate Cancer
Not yet recruiting
Remote Screening and Navigation to Increase Trial Enrollment, INVITE Trial
Bladder Carcinoma, Prostate Carcinoma
RecruitingObservational study
Collection of Blood From Patients With Cancer
Prostate Cancer, Breast Cancer
Active, not recruitingObservational study
Agriculture Health Study
Prostate Cancer, Pesticide Exposures
Active, not recruitingPhase 2
177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer
Prostate Cancer
RecruitingObservational study
Collection of Blood From Patients With Prostate Cancer
Cancer Of Prostate, Prostate Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Boris Yudkevich, MD study director
HaEmek Medical Center, Israel
Genady Zelichenko, MD study director
HaEmek Medical Center, Israel
Ilan Leibovich, MD principal investigator
Meir Medical center, Israel
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing NaviGo in people with Prostate Cancer and Benign Prostatic Hyperplasia, run by HaEmek Medical Center, Israel at 1 site in Israel.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 2 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 16 Mar 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Israel. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Michael mo Cohen, MD (+972-544-764444, dr.m.cohen@gmail.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Create 3D model of the prostate and accurately display the locations of the various biopsies taken during the procedure (time frame: Post procedure ( off-line ) within a 3-5 working days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 16 Mar 2011; AzTrials last refreshed its copy on 6 Nov 2026.